Results showed that FPR1-deficient (KO) PBMCs (CA and AA) failed, at different levels depending whether the mutation of FPR1 occurs in heterozygosis or homozygous, to interact with treated cancer cells with respect to normal PBMCs (CC). This evidence concerns the gene FPR1 and cancer.